智通财经APP讯，复宏汉霖(02696)发布截至2024年12月31日止年度业绩，该集团取得收入人民币57.24亿元(单位下同)，同比增加6.11%;母公司拥有人应占利润8.2亿元，同比增加50.26%;每股盈利1.51元。
截至2024年12月31日止年度，本集团确认研发开支约18.41亿元，较2023年12月31日止年度约14.34亿元增加约4.07亿元。研发开支主要来源于推进技术平台创新、IND申报以及新药的临床试验以加速本集团创新转型。
截至2024年12月31日止年度，本集团的盈利总额约8.205亿元，较截至2023年12月31日止年度盈利约5.46亿元，盈利增加约2.75亿元，主要是由于核心产品陆续实现商业化销售后持续销量扩大所致。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.